Astellas Pharma Inc.

4503

JP3942400007

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,446 JPY

Average target price

2,080 JPY

Spread / Average Target

+43.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	-13.91%	16.81B
ELI LILLY AND COMPANY	+28.10%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.84%	356B
MERCK & CO., INC.	+14.71%	320B
ABBVIE INC.	+4.88%	286B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.77%	142B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
1,452 ^JPY	+0.38%		-9.05%	-13.91%

Apr. 15	Middle East Tensions Blunt Asian Stock Markets Excepting China	MT
Apr. 15	Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	MT

Middle East Tensions Blunt Asian Stock Markets Excepting China	Apr. 15	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	Apr. 15	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	Apr. 14	RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023	Apr. 12	CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy	Apr. 03	MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31	CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	Mar. 28	MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer	Mar. 26	CI
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 22	CI
Bayer to seek approval for menopausal relief drug after third trial win	Mar. 19	RE
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18	CI
Hewlett Packard Enterprise's HPE Asset Upcycling Services Selected by Astellas Pharma	Mar. 14	MT
China Approves Sale of Humanwell Healthcare Unit's Prostate Cancer Treatment	Mar. 06	MT
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan	Mar. 03	CI
Transcript : Astellas Pharma Inc. - Special Call	Feb. 20
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application for PADCEV with KEYTRUDA	Feb. 15	CI
Transcript : Astellas Pharma Inc., Q3 2024 Earnings Call, Feb 05, 2024	Feb. 05
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer	Jan. 30	CI
Astellas Pharma Inc. Announces Strategic Collaboration with Mass General Brigham	Jan. 30	CI
Pfizer Says Application for Bladder Cancer Combination Treatment Validated for Review by European Regulator	Jan. 26	MT
European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Jan. 26	CI
Japan business leaders return to China seeking to bolster cooperation	Jan. 24	RE